CD4 and coinfection: Of the 298,298 study participants, 208 participants (69.8%) were at WHO clinical stages 1 and 2, 98 participants (32.9%) had previously developed an opportunistic infection, 78 participants (26.2%) had a tuberculosis co-infection, and 213 participants (71.55%) had a baseline CD4 count of greater than or equal to 200 cells/mm.3 Additionally, 275 participants (92.3%) had a baseline viral load of less than 1,000 copies/ml, and 208 participants (69.8%) had a baseline body mass index (BMI) greater than 18.5 kg/m2 (Table 3).